This information is for US health care professionals only. SCEMBLIX is a Novartis product and is not associated with any individual users on LinkedIn.
Please see full Prescribing Information for SCEMBLIX at bit.ly/SCEMBPI.
To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
265985 3/23
Company Details
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://scemblix-hcp.com/
- Competitors
- LUMAKRAS® (sotorasib) HCP, Entyvio (vedolizumab), CIMZIA® (certolizumab pegol) HCP, KRYSTEXXA® (pegloticase) HCP, PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) HCP, FABHALTA® (iptacopan) HCP, TEZSPIRE® (tezepelumab-ekko) HCP, ZERBAXA® (ceftolozane and tazobactam) HCP, FASENRA® (benralizumab) HCP, KISQALI HCP.
Scemblix® (Asciminib) Tablets Hcp Questions
Scemblix® (Asciminib) Tablets Hcp's website is https://scemblix-hcp.com/
Scemblix® (Asciminib) Tablets Hcp's LinkedIn profile is https://www.linkedin.com/company/scemblix-hcp
Scemblix® (Asciminib) Tablets Hcp's industry is
Pharmaceutical Manufacturing
Scemblix® (Asciminib) Tablets Hcp's top competitors are
Lumakras® (Sotorasib) Hcp,
Entyvio (Vedolizumab),
Cimzia® (Certolizumab Pegol) Hcp,
Krystexxa® (Pegloticase) Hcp,
Pluvicto® (Lutetium Lu 177 Vipivotide Tetraxetan) Hcp,
Fabhalta® (Iptacopan) Hcp,
Tezspire® (Tezepelumab-Ekko) Hcp,
Zerbaxa® (Ceftolozane And Tazobactam) Hcp,
Fasenra® (Benralizumab) Hcp,
Kisqali Hcp.
Scemblix® (Asciminib) Tablets Hcp's categories are Pharmaceutical Manufacturing
